December 23, 2010
"Scientists are reporting early but promising results from a new drug that blocks HIV as it attempts to invade human cells," HealthDay News/U.S. News & World Report. "The approach differs from most current antiretroviral therapy, which tries to limit the virus only after it has gained entry to cells," the news service adds (Gardner, 12/22). "The drug, being developed by small privately held Hannover-based firm VIRO Pharmaceuticals, is called VIR-576 and reduced the amount of HIV infection in the blood by as much 95 percent in an early-stage trial of 18 patients," Reuters reports (Kelland, 12/23). "At the same time, adverse effects were few and mainly involved injection site reactions, [researchers] reported online in Science Translational Medicine," MedPage Today reports (Smith, 12/22).
No comments have been made.